Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...
F-DOPA PET−guided, dose-escalated, hypofractionated proton beam therapy led to improved OS in older patients with newly ...
The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...
The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic ...
On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term ...
Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who ...
Is watchful waiting for ductal carcinoma in situ (DCIS) safe? Preliminary results of the COMET trial
Ductal carcinoma in situ is a precursor of breast cancer that is usually treated with surgery, radiation therapy, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback